echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Long-range recurrence of gliomas is associated with the development of the lower part of the brain and CD133

    Long-range recurrence of gliomas is associated with the development of the lower part of the brain and CD133

    • Last Update: 2020-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults.
    the current standard of treatment, GBM patients have a medium survival of 18 months.
    relapse is common after treatment.
    that even after surgery, the tumor was well controlled at the initial lesions site, but the recurrence rate at the remote site was between 8% and 43.6%.
    stem cells (Cancer Stem Cell, CSC) in GBM can induce tumor occurrence and differentiation.
    CSC has the ability to metastasis and resist chemotherapy.
    CSC marker CD133 has now been detected from normal mouse and human stem cells.
    CD133 is expressed not only in normal stem cells, but also in many cancer stem cells.
    Tatsu Yamaki of Neurosurgery at Yamash prefecture university in Japan, et al. further studied the correlation between CD133 expression and GBM-tired ventricular region (subventrication zone, SVZ) and GBM long-range recurrence, and published online in February 2020 in NeuroJcolon.
    methods The researchers retrospectively analyzed data on 167 GBM patients.
    the spatial relationship between the tumor and SVZ or cortical on MRI enhancement imaging, the tumor was divided into four groups.
    I. Group: Tumor-tired SVZ region, adjacent to and immersed cortique; II.group: tumor-tired and SVZ region, but not immersed cortique; III.group: tumor not tired and SVZ region, but impregnation cortique; IV.group: tumor not tired and SVZ region, also not immersed corted (Figure 1).
    the initial recurrence mode of GBM from the patient's medical records.
    Factors for predicting long-range recurrence are determined by analyzing patient clinical information (including age, sex, KPS, Ki-67 marker index, surgical and MRI characteristics, etc.), immunogroupization results of tumor specimens, genetic characteristics (including IDH1, MGMT, and BRAF testing), and CD133 expression.
    1. Based on MRI imaging to show the relationship between tumors and the brain chamber, patients were divided into 4 groups.
    A.I. Group: Tumor-tired SVZ region, adjacent to and soaked cortique; B.II.group: tumor-affected SVZ region, but not immersed cortique; C.III.group: tumor not tired and SVZ region, but leaching cortique; D.IV.group: Tumors neither affected SVZ region nor soaked cortique.
    results showed that the CD133 expression rate of tumors in the SVZ region was higher than that of tumors in the SVZ region .
    21% of patients had long-range recurrence, and no significant differences were found in 4 groups of recurrence patterns.
    analysis of single variables, multivariables, and tendency matching shows that the high expression of CD133 is related to the earlier occurrence of long-range recurrence (P<0.0001, P.001 and P.0084, respectively).
    In a comprehensive analysis of the four sets of recurrence patterns shown in CD133 expression and MRI, it was found that CD133 expression levels ≥15% of group III. Group III. that GBM, which is not tired of the SVZ region and soaked in cort matter, is most commonly relapsed over long distances (70%) (Figure 2).
    Figure 2. CD133 expression combined with tumor MRI characteristics to predict long-range recurrence rates.
    The study showed that combined with GBM's CD133 expression level and mri imaging to show a comprehensive analysis of tumor-tired regions, it helped to predict GBM's long-range recurrence.
    : The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
    , editing, copying, cutting, recording, etc. without permission.
    be used with a license, the source must also be indicated.
    welcome to forward and share.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.